Cover
Cover - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 21, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Sep. 30, 2022 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 000-32141 | |
Entity Registrant Name | NUTRA PHARMA CORP | |
Entity Central Index Key | 0001119643 | |
Entity Tax Identification Number | 91-2021600 | |
Entity Incorporation, State or Country Code | CA | |
Entity Address, Address Line One | 1537 NW 65th Avenue | |
Entity Address, City or Town | Plantation | |
Entity Address, State or Province | FL | |
Entity Address, Postal Zip Code | 33313 | |
City Area Code | 954 | |
Local Phone Number | 509–0911 | |
Entity Current Reporting Status | No | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 7,596,852,214 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash | $ 90,910 | |
Accounts receivable | 21,580 | 45,998 |
Inventory, current portion | 49,346 | 31,289 |
Other receivable | 3,000 | 6,000 |
Convertible notes receivable | 270,896 | 273,480 |
Prepaid expenses and other current assets | 117,650 | 86,150 |
Total current assets | 462,472 | 533,827 |
Inventory, less current portion | 90,380 | 98,880 |
Property and equipment, net | 85,606 | 44,701 |
Operating lease right-of-use assets | 43,397 | 93,811 |
Security deposit | 8,803 | 8,803 |
Total assets | 690,658 | 780,022 |
Current liabilities: | ||
Accounts payable | 712,757 | 672,372 |
Accrued expenses | 963,526 | 851,470 |
Accrued payroll due to officers | 1,173,693 | 1,053,693 |
Deferred revenue to a related party | 111,011 | |
Accrued interest to related parties | 145,508 | 147,768 |
Due to officer | 61,439 | 199,726 |
Derivative liabilities | 5,097,169 | 10,537,344 |
Other debt, net of discount, current portion | 7,860,452 | 7,598,325 |
SBA notes payable, current portion | 2,930 | 2,121 |
Operating lease obligations, current portion | 20,003 | 77,673 |
Total current liabilities | 16,148,488 | 21,140,492 |
Convertible note, less current portion | 4,707 | 369,401 |
SBA notes payable, less current portion | 146,970 | 147,779 |
Total liabilities | 16,300,165 | 21,657,672 |
Commitments and Contingencies | ||
Stockholders’ deficit: | ||
Preferred stock, $0.001 par value, 20,000,000 shares authorized and 12,000,000 Series B Preferred shares issued and outstanding at September 30, 2022 and December 31, 2021 | 12,000 | 12,000 |
Common stock, $0.001 par value, 12,000,000,000 shares authorized: 7,596,852,214 and 7,330,985,964 shares issued and outstanding at September 30, 2022 and December 31, 2021 | 7,596,852 | 7,330,986 |
Additional paid-in capital | 53,565,739 | 53,508,353 |
Accumulated deficit | (76,784,098) | (81,728,989) |
Total stockholders’ deficit | (15,609,507) | (20,877,650) |
Total liabilities and stockholders’ deficit | $ 690,658 | $ 780,022 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 12,000,000,000 | 12,000,000,000 |
Common stock, shares issued | 7,596,852,214 | 7,330,985,964 |
Common stock, shares outstanding | 7,596,852,214 | 7,330,985,964 |
Series B Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 20,000,000 | 20,000,000 |
Preferred stock, shares issued | 12,000,000 | 12,000,000 |
Preferred stock, shares outstanding | 12,000,000 | 12,000,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Statement [Abstract] | ||||
Net sales | $ 24,624 | $ 19,266 | $ 66,814 | $ 71,748 |
Net sales to a related party | 84,580 | 154,966 | ||
Cost of sales | (41,051) | (9,644) | (116,254) | (24,284) |
Gross profit | 68,153 | 9,622 | 105,526 | 47,464 |
Operating expenses: | ||||
Selling, general and administrative - including stock based compensation of $0 and $64,750 for the three months ended September 30, 2022 and 2021, and $20,500 and $66,195 for the nine months ended September 30, 2022 and 2021, respectively | 326,473 | 556,932 | 991,557 | 1,501,689 |
Bad debt expense (recovery) - related party | (21,799) | (35,000) | 38,000 | |
Total operating expenses | 304,674 | 521,932 | 991,557 | 1,539,689 |
Loss from operations | (236,521) | (512,310) | (886,031) | (1,492,225) |
Other income (expenses) | ||||
Other income | 4,210 | 4,750 | 16,215 | 6,465 |
Interest expense | (195,424) | (131,482) | (580,075) | (346,792) |
Interest expense to related parties | (4,272) | (4,504) | (12,740) | (13,881) |
Change in fair value of convertible notes and derivatives | 1,019,736 | 16,133,270 | 6,569,581 | (12,824,783) |
Stock based loan modification cost | (10,500) | (10,500) | (107,500) | |
Loss on settlement of debt and accrued expense, net | (56,339) | (151,559) | (485,836) | |
Total other income (expenses) | 813,750 | 15,945,695 | 5,830,922 | (13,772,327) |
Income (loss) before income taxes | 577,229 | 15,433,385 | 4,944,891 | (15,264,552) |
Provision for income taxes | ||||
Net income (loss) | $ 577,229 | $ 15,433,385 | $ 4,944,891 | $ (15,264,552) |
Net income (loss) per share - basic and diluted | $ 0 | $ 0 | $ 0 | $ 0 |
Weighted average number of shares outstanding during the period - basic | 7,592,286,997 | 7,289,196,290 | 7,471,152,031 | 7,201,163,176 |
Weighted average number of shares outstanding during the period - diluted | 15,597,613,916 | 12,670,053,386 | 15,104,777,470 | 7,201,163,176 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Statement [Abstract] | ||||
Stock based compensation | $ 0 | $ 64,750 | $ 20,500 | $ 66,195 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) | Preferred Stock [Member] Series A Preferred Stock [Member] | Preferred Stock [Member] Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Dec. 31, 2020 | $ 3,000 | $ 6,955,197 | $ 50,181,456 | $ (68,633,468) | $ (11,493,815) | |
Beginning balance, shares at Dec. 31, 2020 | 3,000,000 | 6,955,197,214 | ||||
Common stock issued for debt modification and penalty | $ 25,000 | 82,500 | 107,500 | |||
Common stock issued for debt modification and penalty, shares | 25,000,000 | |||||
Net income (loss) | (15,264,552) | (15,264,552) | ||||
Issuance of common stock in exchange for services to consultants | $ 25,000 | 125,000 | 150,000 | |||
Issuance of common stock in exchange for services to consultants, shares | 25,000,000 | |||||
Common stock issued for settlement of debt | $ 62,939 | 472,848 | 535,787 | |||
Common stock issued for settlement of debt, shares | 62,938,750 | |||||
Common stock issued for conversion of debt | $ 240,350 | 2,104,049 | 2,344,399 | |||
Common stock issued for conversion of debt, shares | 240,350,000 | |||||
Ending balance, value at Sep. 30, 2021 | $ 3,000 | $ 7,308,486 | 52,965,853 | (83,898,020) | (23,620,681) | |
Ending balance, shares at Sep. 30, 2021 | 3,000,000 | 7,308,485,964 | ||||
Beginning balance, value at Jun. 30, 2021 | $ 3,000 | $ 7,267,620 | 52,816,687 | (99,331,405) | (39,244,098) | |
Beginning balance, shares at Jun. 30, 2021 | 3,000,000 | 7,267,619,714 | ||||
Net income (loss) | 15,433,385 | 15,433,385 | ||||
Issuance of common stock in exchange for services to consultants | $ 20,000 | 97,000 | 117,000 | |||
Issuance of common stock in exchange for services to consultants, shares | 20,000,000 | |||||
Common stock issued for settlement of debt | $ 20,866 | 52,166 | 73,032 | |||
Common stock issued for settlement of debt, shares | 20,866,250 | |||||
Ending balance, value at Sep. 30, 2021 | $ 3,000 | $ 7,308,486 | 52,965,853 | (83,898,020) | (23,620,681) | |
Ending balance, shares at Sep. 30, 2021 | 3,000,000 | 7,308,485,964 | ||||
Beginning balance, value at Dec. 31, 2021 | $ 12,000 | $ 7,330,986 | 53,508,353 | (81,728,989) | (20,877,650) | |
Beginning balance, shares at Dec. 31, 2021 | 12,000,000 | 7,330,985,964 | ||||
Common stock issued for debt modification and penalty | $ 10,500 | 10,500 | ||||
Common stock issued for debt modification and penalty, shares | 10,500,000 | |||||
Net income (loss) | 4,944,891 | 4,944,891 | ||||
Common stock issued for settlement of debt | $ 243,366 | 33,386 | 276,752 | |||
Common stock issued for settlement of debt, shares | 243,366,250 | |||||
Common stock issued for conversion of debt | $ 12,000 | 24,000 | 36,000 | |||
Common stock issued for conversion of debt, shares | 12,000,000 | |||||
Ending balance, value at Sep. 30, 2022 | $ 12,000 | $ 7,596,852 | 53,565,739 | (76,784,098) | (15,609,507) | |
Ending balance, shares at Sep. 30, 2022 | 12,000,000 | 7,596,852,214 | ||||
Beginning balance, value at Jun. 30, 2022 | $ 12,000 | $ 7,586,352 | 53,565,739 | (77,361,327) | (16,197,236) | |
Beginning balance, shares at Jun. 30, 2022 | 12,000,000 | 7,586,352,214 | ||||
Common stock issued for debt modification and penalty | $ 10,500 | 10,500 | ||||
Common stock issued for debt modification and penalty, shares | 10,500,000 | |||||
Net income (loss) | 577,229 | 577,229 | ||||
Ending balance, value at Sep. 30, 2022 | $ 12,000 | $ 7,596,852 | $ 53,565,739 | $ (76,784,098) | $ (15,609,507) | |
Ending balance, shares at Sep. 30, 2022 | 12,000,000 | 7,596,852,214 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Cash flows from operating activities: | ||||||
Net income (loss) | $ 577,229 | $ 15,433,385 | $ 4,944,891 | $ (15,264,552) | ||
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||
Bad debt expense - related party | (21,799) | (35,000) | 38,000 | |||
Accrued interest expense for amount due to officer | 3,512 | 5,788 | $ 7,520 | |||
Loss on settlement of debt and accrued expense | 56,339 | 151,559 | 485,836 | |||
Depreciation | 5,898 | 2,793 | 17,088 | 6,178 | ||
Stock-based compensation | 0 | 64,750 | 20,500 | 66,195 | ||
Stock-based loan modification cost | 10,500 | 10,500 | 107,500 | |||
Amortization of convertible notes receivable discount | (16,215) | (6,465) | ||||
Change in fair value of convertible notes and derivatives | (1,019,736) | (16,133,270) | (6,569,581) | 12,824,783 | ||
Amortization of loan discount | 404,549 | 232,117 | ||||
Amortization of operating lease right-of-use assets | 50,414 | 35,995 | ||||
Changes in operating assets and liabilities: | ||||||
Decrease (increase) in accounts receivable | 24,418 | (4,359) | ||||
Increase in other receivable | (12,000) | (9,000) | ||||
Increase in inventory | (9,557) | (47,737) | ||||
Increase in prepaid expenses and other current assets | (52,000) | (98,150) | ||||
Decrease in accounts payable | 40,385 | 12,516 | ||||
Increase in accrued expenses | 112,056 | 56,973 | ||||
Increase in accrued payroll due to officers | 120,000 | 125,500 | ||||
Increase in deferred revenue to a related party | 111,011 | |||||
Decrease in accrued interest to related parties | (2,260) | (26,120) | ||||
Decrease in operating lease obligations | (57,670) | (51,787) | ||||
Net cash used in operating activities | (708,400) | (1,510,789) | ||||
Cash flows from investing activities: | ||||||
Convertible notes receivable advances | (16,451) | (242,500) | ||||
Convertible notes receivable repayments | 50,250 | 50,250 | ||||
Acquisition of equipment | (57,993) | (34,768) | ||||
Net cash used in investing activities: | (24,194) | (277,268) | ||||
Cash flows from financing activities: | ||||||
Loans from officer | 62,201 | 56,900 | ||||
Repayment of officer loans | (204,000) | (120,250) | ||||
Proceeds from convertible notes | 710,000 | 1,976,560 | ||||
Repayment of convertible notes | (60,994) | (65,028) | ||||
Advances from an unrelated third party | 251,340 | |||||
Repayments of other notes payable | (116,863) | (15,375) | ||||
Net cash provided by financing activities | 641,684 | 1,832,807 | ||||
Net increase(decrease) in cash | (90,910) | 44,750 | ||||
Cash - beginning of period | $ 44,750 | 90,910 | ||||
Cash - end of period | $ 90,910 | $ 44,750 | 44,750 | $ 90,910 | ||
Supplemental Cash Flow Information: | ||||||
Cash paid for interest | 84,460 | 41,951 | ||||
Cash paid for income taxes | ||||||
Non Cash Financing and Investing: | ||||||
Common stock issued in settlement of notes | 287,252 | 535,787 | ||||
Common stock issued for conversion of debt | 36,000 | 2,344,399 | ||||
Warrants issued with Debt--Debt discount | 100,000 | |||||
Increase of right-of-use asset due to lease renewal | 4,102 | |||||
Increase of operating lease liabilities due to lease renewal | 4,102 | |||||
Reclassification of rental receivable to convertible notes receivable | $ 15,000 | $ 6,000 |
BASIS OF PRESENTATION AND SUMMA
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K from which the accompanying condensed consolidated balance sheet dated December 31, 2021 was derived. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $ 76,784,098 15,686,016 15,609,507 There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $ 64,895 150,000 The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. We classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at September 30, 2022 and December 31, 2021, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $ 0 48,000 294,162 Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended September 30, 2022, one customer accounted for 77 10 70 25 100 Operating Lease Right-of-Use Asset and Liability The Company accounts for leases in accordance with Accounting Standards Update (“ASU”) 2016-02, Leases In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to other income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that was issued before the adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity that did not contain an embedded derivative that required bifurcation, the conversion feature was evaluated to determine if the rate of conversion was below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt was recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt was recorded net of the discount for the BCF. The discount was amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, Derivatives and Hedging Embedded Derivatives Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 7 Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. Income Taxes The Company recorded no Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount (See Note 13). Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Income (Loss) Per Share Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share SCHEDULE OF NET INCOME (LOSS) PER SHARE 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Basic and diluted numerator: Net income (loss) - basic $ 577,229 $ 15,433,385 $ 4,944,891 $ (15,264,552 ) Effect of dilutive securities: Change in fair value of convertible notes (730,917 ) (2,595,948 ) (805,027 ) - Interest on convertible debt 61,313 91,454 213,995 - Net income (loss) - diluted $ (92,375 ) $ 12,928,891 $ 4,353,859 $ (15,264,552 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 7,592,286,997 7,289,196,290 7,471,152,031 7,201,163,176 Effect of dilutive securities: Convertible debt 8,005,326,919 5,380,857,096 7,633,625,439 - Options and warrants - - - - Weighted-average common shares outstanding - diluted (1) 15,597,613,916 12,670,053,386 15,104,777,470 7,201,163,176 Net income (loss) per share - basic and diluted $ (0.00 ) $ 0.00 $ 0.00 $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares. The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because for the three months ended September 30, 2022 and 2021, the exercise prices of the options and warrants were greater than the average market price of the common shares: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - - Convertible notes payable - - Total 447,014,285 108,175,000 The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because (1) for the nine months ended September 30, 2022, the exercise prices of the options and warrants were greater than the average market price of the common shares and (2) for the nine months ended September 30, 2021, the effect of including these potential shares was antidilutive due to a net loss: September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - 1,201,380,692 Convertible notes payable - 4,434,302,953 Total 447,014,285 5,743,858,645 Recent Adopted Accounting Pronouncements As of January 1, 2022, the Company adopted ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity As of January 1, 2022, the Company adopted ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. The adoption did not have a material effect on the accompanying consolidated financial statements. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | 2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at September 30, 2022 and December 31, 2021: SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 200,103 $ - $ - $ 200,103 Derivative liabilities $ 4,897,066 $ - $ 4,897,066 $ - Convertible notes at fair value $ 1,745,305 $ - $ - $ 1,745,305 Total Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 710,585 $ - $ - $ 710,585 Derivative liabilities $ 9,826,759 $ - $ 9,826,759 $ - Convertible notes at fair value $ 2,855,709 $ - $ - $ 2,855,709 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the nine months ended September 30, 2022 and the year ended December 31, 2021: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description September 30, 2022 December 31, 2021 Beginning balance $ 710,585 $ 189,543 Purchases, issuances, and settlements 100,000 590,885 Day one loss on value of hybrid instrument (1) Repayments in cash Conversion to common stock Total gain included in earnings (1) (1) (610,482 ) (69,843 ) Ending balance $ 200,103 $ 710,585 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 2.79 % to 3.92 % risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 411 %, (4) zero expected dividends, (5) exercise price set forth in the agreements, (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. We valued derivative liabilities using the number of potential convertible shares for warrants in equity and convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at September 30, 2022. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit and the equity environment is tainted, and therefore all convertible debt and options and warrants should be accounted for as liabilities. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at September 30, 2022 and December 31, 2021: SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS Conversion Price - Lower of Fixed Price or Percentage of VWAP for Look-back Period Debenture Face Amount Interest Rate Default Interest Rate Discount Rate Anti-Dilution Adjusted Price % of stock price for look-back period Look-back Period September 30, 2022 $ 711,446 8 10 20 24 N/A $ 0.00040 0.00048 50 60 3 25 December 31, 2021 $ 762,446 8 10 20 24 N/A $ 0.00050 0.00097 50 60 3 25 Using the stated assumptions summarized in the table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the nine months ended September 30, 2022 and the year ended December 31, 2021: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description September 30, 2022 December 31, 2021 Beginning balance $ 2,855,709 $ 1,832,439 Purchases and issuances - 132,000 Day one loss on value of hybrid instrument (1) (1) - 2,042,612 Loss (gain) from change in fair value (1) (1) (1,029,404 ) 1,233,538 Repayments in cash (45,000 ) (40,480 ) Conversion to common stock (36,000 ) (2,344,399 ) Ending balance $ 1,745,305 $ 2,855,709 (1) The losses (gains) related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES
INVENTORIES | 9 Months Ended |
Sep. 30, 2022 | |
Inventory Disclosure [Abstract] | |
INVENTORIES | 3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At September 30, 2022 and December 31, 2021, inventories were as follows: SCHEDULE OF INVENTORIES September 30, 2022 December 31, 2021 Raw Materials $ 131,005 $ 126,349 Finished Goods 8,721 3,820 Total Inventories 139,726 130,169 Less: Long-term inventory (90,380 ) (98,880 ) Current portion $ 49,346 $ 31,289 |
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT | 9 Months Ended |
Sep. 30, 2022 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY AND EQUIPMENT | 4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at September 30, 2022 and December 31, 2021: SCHEDULE OF PROPERTY AND EQUIPMENT September 30, 2022 December 31, 2021 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 162,557 104,564 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 324,879 266,886 Less: Accumulated depreciation (239,273 ) (222,185 ) Property and equipment, net $ 85,606 $ 44,701 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At September 30, 2022, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the nine-months ended September 30, 2022 and 2021 was $ 17,088 6,178 5,898 2,793 |
DUE TO_FROM OFFICER
DUE TO/FROM OFFICER | 9 Months Ended |
Sep. 30, 2022 | |
Due Tofrom Officer | |
DUE TO/FROM OFFICER | 5. DUE TO/FROM OFFICER At September 30, 2022, the net balance due to Rik Deitsch, and the companies majority owned and controlled by him (collectively referred to as “Due to Officer”) in the aggregate is $ 61,439 , which net balance is unsecured and accruing interest at 4 204,000 and were advanced $ 62,201 on this balance. Additionally, accrued interest on the outstanding balance was $ 3,512 and is included in the due to officer account. The Company had previously fully reserved receivables from companies owned by the Company’s CEO. For the nine months ended September 30, 2021, we recorded a bad debt expense of $ 38,000 21,799 and $ 35,000 , respectively. At December 31, 2021, the net balance due to Rik Deitsch, and the companies majority owned and controlled by him is $ 199,726 4 182,741 105,780 7,520 |
DEBTS
DEBTS | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
DEBTS | 6. DEBTS Debts consist of the following at September 30, 2022 and December 31, 2021: SCHEDULE OF DEBT September 30, 2022 December 31, 2021 Notes payable – Unrelated third parties (Net of discount of $ 19,106 0 $ 1,285,287 $ 1,135,257 Convertible notes payable – Unrelated third parties (Net of discount of $ 183,570 283,429 4,609,567 3,751,760 Convertible notes payable, at fair value (4) 1,745,305 2,855,709 Other advances from an unrelated third party (5) 225,000 225,000 SBA notes payable(6) 149,900 149,900 Ending balances 8,015,059 8,117,626 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (4,707 ) (369,401 ) Less: Long-term portion- SBA notes payable (146,970 ) (146,970 ) Current portion $ 7,863,382 $ 7,600,446 (1) During 2010 we borrowed $ 200,000 nine months interest calculated at 10% for the first month plus 12% December 31, 2016 40,000 10,000 15,000 145,508 147,768 4,272 4,504 12,740 13,881 (2) At September 30, 2022 and December 31, 2021, the balance of $ 1,285,287 1,135,257 19,106 0 ● In August 2016, we issued two Promissory Notes for a total of $ 200,000 100,000 12% 101,818 21,023 104,000 88,500 15,500 88,500 91,156 60,037 51,856 The remaining principal balance of $91,156 and accrued interest of $60,037 is being disputed in court and negotiation for settlement ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $ 350,000 50,000 175,000 25,000 25,000 142,858 5,714,326 450,000 350,000 100,000 281,772 281,772 ● At December 31, 2012, we owed University Centre West Ltd. approximately $ 55,410 ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $ 10,000 10% 6,541 5,783 ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $ 75,000 2% 5,000,000 25,000 50,000 83,434 74,334 ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $ 50,000 2% 50,000 76,634 67,534 ● A promissory note originally issued to an unrelated third party in August 2016 was restated in September 2019 in the amount of $ 333,543 2.0% 20,000,000 10,000,000 6,000 5,895 333,543 248,378 187,673 ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $ 75,000 10% 15,000 60,000 15,900 15,000 1,371 ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $ 50,000 2% 72,934 63,834 ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $ 12,500 10% 6,698 5,750 ● During July 2017, we received a loan for a total of $ 200,000 15% 130,401 40,000 5,000 2,000 34,976 42,698 44,478 14,376 33,874 130,401 33,874 ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $ 50,000 10,000 50,000 ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $ 120,000 20,000 50,000 125,000,000 87,500 37,500 36,000,000 10,000,000 32,200 70,000 14,000 10,000 74,000 74,000 ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $ 18,000 3,000 18,000 2,000 ● During January 2022, the Company received a loan for $ 199,000 63.76% 4,975 850 2,300 68,023 2,675 130,977 ● During June 2022, the Company entered a Purchase and Sale of Future Receipts Agreement with a non-related party. This third party purchased $ 87,000 60,000 87,000 29,685 12,369 885 38,839 16,431 31,730 (3) At September 30, 2022 and December 31, 2021, the balance of $ 4,609,567 3,751,760 183,570 283,429 ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $ 60,000 10,000 60,000 ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $ 618,250 62,950 0.0003 0.001 255,655 62,950 28,421 During February 2019, we issued convertible notes payable of $ 55,000 5,000 0.0005 55,000 9,200 128,400 0.001 92,100,000 36,300,000 541 195,178 During May 2019, we restated two convertible notes payable with additional original issue discount of $ 6,400 During February, November and December 2019, we issued three convertible promissory notes to the unrelated third party for $ 174,500 14,500 0.0002 0.000275 During 2019, repayments of $ 13,500 87,100 800,000,000 At December 31, 2019, the principal balance of the notes, net of discount of $ 17,370 736,180 17,370 10,000 During the year ended December 31, 2020, we issued convertible notes payable of $ 555,600 53,600 287,400 268,200 0.0002 0.0008 1,000,000 22,000 700 57,500 7,500 71,875,000 0.002 50,000 7,500 0 106,032 At December 31, 2020, the principal balance of the notes, net of discount of $ 101,448 1,276,902 83,720 During the first quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $ 717,667 93,609 864,225 112,725 539,351 70,350 358,800 46,800 0.0003 0.002 228,563 August 29, 2022 During December 2021, in connection with the issuance of three of the above mentioned convertible notes of $ 172,500 22,500 246,428,571 0.002 150,000 22,500 105,814 409,374 During March 2021, the remaining balance of promissory note of $ 30,000 0.01 12% 1,000 7,323 7,244 15,433 22,677 513 793 1,756 1,951 During March 2021, in connection with the settlement of the $ 6,000 11,000 11,000,000 6,000 104,500 5,000 98,500 8,500 12,000 2,000,000 4,000 15,200 4,500 11,200 During August 2021, the promissory note of $ 166,926 0.002 183,619 16,693 20,866,250 16,693 54,252 16,693 37,559 166,926 0.002 16,693 10,000,000 10,000 10,000 166,926 16,693 0.002 16,693 During the first quarter of 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 172,500 22,500 0.0005 0.0008 During the second quarter of 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 379,500 49,500 0.0006 0.0008 During the third quarter of 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 264,500 34,500 0.0005 0.0006 During January and May 2022, in connection with the issuance of one of the above mentioned convertible notes of $ 115,000 15,000 164,285,714 0.002 100,000 15,000 93,748 During June 2022, we repaid a convertible notes payable originated in May 2021 in cash for $ 5,750 108,500 222,500,000 108,500 222,500 114,000 During August 2022, we made repayment of $ 3,000 17,250 3,000 500,000 500 500 At the date of this report, $ 3,125,268 The total discount amortization on all notes for the three and nine months ended September 30, 2021 was $ 123,813 388,994 91,455 213,924 183,570 4,609,567 283,430 3,751,760 (4) At September 30, 2022 and December 31, 2021, the balance of $ 1,745,305 2,855,709 ● The remaining balance of $ 20,000 120,000 55% 20,000 24,217 21,183 80,395 84,768 ● During May 2017, we issued a Convertible Debenture in the amount of $ 64,000 May 4, 2018 60% twenty 20% 12,629 16,728 14,834 48,929 70,418 ● During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. During October 2020, the Note holder sold the remaining debt principal value as of October 22, 2020 of $ 509,301 234,417 250,000 250,000 8% 286,969 We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date 275,000 82,022 32,657 714,044 946,639 ● During July 2018, we issued a convertible debenture in the amount of $ 50,000 8% 24% 46,734 50,000 42,367 33,490 167,940 202,491 ● During August 2018, we issued a convertible debenture in the amount of $ 20,000 8% 24% 17,829 20,000 16,500 12,923 66,363 79,815 ● During January 2019, the principal balance of $ 60,000 75,000 15,900 75,900 50% 75,900 20,000 75,900 100,000,000 20,000 140,000 55,900 111,800 156,000 ● During February 2019, we issued a convertible promissory note to an unrelated third party in the amount up to $ 1,000,000 0.0005 372,374 20,199 132,000 40,480 45,000 27,000 11,412 2,042,612 750,000,000 100,000 275,000 500,000,000 175,000 425,000 240,350,000 120,175 2,344,399 12,000,000 6,000 36,000 37,917 37,917 88,917 75,834 355,668 ● During June 2019, we issued a convertible promissory note to an unrelated third party for $ 240,000 40,000 16,000,000 4,688 The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion 240,000 240,000 480,000 960,000 (5) At September 30, 2022 and December 31, 2021, the balance of $ 225,000 (6) During May 2020, we entered into a two-year loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $ 64,895 1% During April and June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) considering the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $ 150,000 3.75% 731 5,000 13,124 8,906 SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT Years Amount 2022(2 months remaining) $ 525 2023 3,222 2024 3,345 2025 3,472 2026 3,605 Thereafter 135,731 149,900 Less: Long-term portion - SBA notes payable (146,970 ) Current portion $ 2,930 |
STOCKHOLDERS_ DEFICIT
STOCKHOLDERS’ DEFICIT | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
STOCKHOLDERS’ DEFICIT | 7. STOCKHOLDERS’ DEFICIT Authorized Shares On November 18, 2021, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 8,000,000,000 12,000,000,000 Series A Preferred Stock Effective October 30, 2017, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination to authorize the issuance of 20,000,000 Effective October 30, 2017 the Board of Directors authorized the issuance of 3,000,000 1. The Series A Preferred voted with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series A Preferred is entitled to one thousand votes per share. 2. The Series A Preferred was not entitled to dividends unless the Company paid cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series A Preferred was entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series A Preferred would have the same record and payment date and terms as the dividend payable on the common stock. 3. The Series A Preferred did not have any redemption rights. Effective November 15, 2021, the Board of Directors authorized an exchange of 3,000,000 Upon return of 100% of Series A Preferred Stock to the Company, the entire class of Series A Preferred Stock was cancelled and the associated Certificate of Determination was filed with the Secretary of State of California. Series B Preferred Stock Effective March 2021, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination for its Series B Preferred Stock. The Series B Preferred Stock has a par value of $ 0.001 12,000,000 Terms of the Series B Preferred include the following: 1. The Series B Preferred votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series B Preferred is entitled to one thousand votes per share. 2. The Series B Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series B Preferred will be entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series B Preferred will have the same record and payment date and terms as the dividend payable on the common stock. The liquidation value of Series B Preferred is $ 0 3. Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series B Preferred then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount in cash equal to $ 0.133 4. The Series B Preferred does not have any redemption rights. During November 2021, the Board of Directors approved resolutions for the issuance of a total of 9,000,000 540,000 Effective November 15, 2021, the Board of Directors authorized an exchange of 3,000,000 Common Stock Issued for Conversion of Convertible Debt During February 2022, the Noteholder received 12,000,000 6,000 36,000 Common Stock Issued for Settlement of Debt During February 2022, in connection with the settlement of $ 16,693 183,619 20,866,250 54,252 37,559 During May 2022, in connection with the settlement of a total of $ 108,500 222,500,000 108,500 222,500 114,000 Common Stock Issued for Debt Modification and Penalty During August 2022, we issued 10,000,000 183,619 10,000 During August 2022, we issued 500,000 17,250 500 Common Stock Issued for Consulting Service During July 2021, the Company signed an agreement with a consultant for services for twelve months. The 5,000,000 41,000 0 20,500 |
STOCK WARRANTS
STOCK WARRANTS | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
STOCK WARRANTS | 8. STOCK WARRANTS Common Stock Warrants During August 2020, convertible promissory notes of $ 38,500 7,550 16,500 1,650 0.001 541 195,178 SCHEDULE OF WARRANTS ISSUED Month of Issuance Number of Warrants Month of Expiration August, 2020 92,100,000 August, 2022 October, 2020 36,300,000 October, 2022 During November and December, 2020, the Company granted the 71,875,000 0.002 57,500 7,500 57,500 0 106,032 During December 2021, in connection with the issuance of three of the convertible notes of $ 172,500 22,500 246,428,571 0.002 105,814 409,374 During January and May 2022, in connection with the issuance of the convertible note of $ 115,000 15,000 164,285,714 0.002 93,748 A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2021 and the nine months ended September 30, 2022: SUMMARY OF WARRANTS OUTSTANDING Number Of Weighted Balance December 31, 2020 202,775,000 $ 0.0017 Exercised - - Issued 410,403,571 0.0014 Expired (166,475,000 ) 0.0015 Balance December 31, 2021 446,703,571 $ 0.0017 Exercised - - Issued 164,285,714 0.0020 Expired (163,975,000 ) 0.0014 Balance September 30, 2022 447,014,285 $ 0.0019 The following table summarizes information about fixed-price warrants outstanding as of September 30, 2022 and December 31, 2021 : SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price September 30, 2022 $ 0.001 0.002 447,014,285 0.30 $ 0.0019 December 31, 2021 $ 0.001 0.002 446,703,571 0.67 $ 0.0017 At September 30, 2022, the aggregate intrinsic value of all warrants outstanding and expected to vest was $ 0 0.0008 no |
ACCRUED EXPENSES
ACCRUED EXPENSES | 9 Months Ended |
Sep. 30, 2022 | |
Payables and Accruals [Abstract] | |
ACCRUED EXPENSES | 9. ACCRUED EXPENSES Accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES September 30, 2022 December 31, Accrued consulting fees $ 161,550 $ 161,550 Accrued payroll taxes 227,912 215,543 Accrued interest 571,151 469,040 Accrued others 2,913 5,337 Total $ 963,526 $ 851,470 |
PREPAID EXPENSES
PREPAID EXPENSES | 9 Months Ended |
Sep. 30, 2022 | |
Prepaid Expenses | |
PREPAID EXPENSES | 10. PREPAID EXPENSES Prepaid expenses and other current assets consist of the following: SCHEDULE OF PREPAID EXPENSES September 30, 2022 December 31, Supplier advances for future purchases $ 339,162 $ 294,162 Reserve for supplier advances (294,162 ) (294,162 ) Net supplier advances 45,000 - Prepaid professional fees 72,650 65,650 Deferred stock compensation - 20,500 Total $ 117,650 $ 86,150 We performed an evaluation of our inventory and related accounts at September 30, 2022 and December 31, 2021, and increased the reserve on supplier advances for future venom purchases by $ 0 48,000 294,162 |
CONVERTIBLE NOTES RECEIVABLE
CONVERTIBLE NOTES RECEIVABLE | 9 Months Ended |
Sep. 30, 2022 | |
Convertible Notes Receivable | |
CONVERTIBLE NOTES RECEIVABLE | 11. CONVERTIBLE NOTES RECEIVABLE During March through November 2021, we purchased five convertible notes from an unrelated third party (the “Third Party”) for a total of $ 286,550 26,050 0.01 one year During March through September 2022, we purchased five convertible notes from the Third Party for a total of $ 34,596 3,145 0.01 Repayments of $ 50,250 0 13,070 270,896 273,480 Amortization for all the convertible notes receivable was $ 4,210 4,750 16,215 6,465 268,750 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | 12. COMMITMENTS AND CONTINGENCIES Operating Leases ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $ 6,900 In February of 2021, we signed an updated lease with extended terms through January 1, 2023. The lease calls for monthly payments of approximately $ 6,500 SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION September 30, December 31, 2022 2021 Lease cost Operating lease cost $ 60,297 $ 80,396 Short-term lease cost - - Total lease cost $ 60,297 $ 80,396 Balance sheet information Operating ROU Assets $ 43,397 $ 93,811 Operating lease obligations, current portion 20,003 77,673 Operating lease obligations, non-current portion - - Total operating lease obligations $ 20,003 $ 77,673 Weighted average remaining lease term (in years) – operating leases 0.25 1 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows: Cash paid for amounts included in the measurement of operating lease liabilities $ 67,553 $ 95,846 Future minimum payments under these lease agreements are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 (Remaining three months) $ 20,270 Total future lease payments $ 20,270 Less imputed interest 267 Total $ 20,003 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years 500,000 8 50,000 0.18 142,500 During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 3,000 31,750 1,000,000 19,150 1,500,000 Litigation CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $ 100,000 91,156 60,037 Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants’ filed a Memorandum of Law in Opposition to Plaintiff’s Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021. On August 31, 2022, the Court entered an Order Granting in Part and Denying in Part the SEC’s Motion for Partial Summary Judgment. Specifically, the Court granted the SEC’s Motion for Partial Summary Judgment on Claim 7 (Section 5 of the Securities Act) against the Company and Mr. Deitsch, Claim 8 (Section 13(d) of the Exchange Act and Rule 13d-2(a) thereunder) against Mr. Deitsch, Claim 9 (Section 16(a) of the Exchange Act and Rule 16a-3 thereunder) against Mr. Deitsch, and Claim 10 (Section 13(a) of the Exchange Act and Rule 13a-11 thereunder) against the Company, but denied the SEC’s Motion for Partial Summary Judgment on Claim 14 (alleged aiding and abetting Nutra Pharma’s violation of Section 13(a) of the Exchange Act, and Rule 13a-11 thereunder) against Mr. Deitsch. The remedies pertaining to the claims addressed in the SEC’s Partial Summary Judgment will be determined by the Court at a later date. On September 16, 2022, Mr. Deitsch filed a Motion to Supplement his Initial Disclosures pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure and to re-open discovery for the limited purpose of obtaining discovery from certain Nutra Pharma shareholders identified by Mr. Deitsch in his supplement to the initial disclosures. The Magistrate Judge assigned to the case granted Deitsch’s Motion on that same day and discovery has been re-opened on a limited basis. When the discovery in the case is complete, the case will proceed to trial on the remaining claims in the SEC’s Second Amended Complaint that were not addressed in the SEC’s Partial Summary Judgment. The Company disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended |
Sep. 30, 2022 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | 13. RELATED PARTY TRANSACTIONS The Company acts as a product formulator and contract manufacturer for Avini Health. The Company’s chief executive officer is an owner of Avini Health and is its chief scientific officer. Commencing in May 2022, the Company sublets a portion of its space to Avini Health under a one-year sublease for a monthly rent of $ 5,000 10,000 As of September 30, 2022 and December 31, 2021, we had the following related party balances: SCHEDULE OF RELATED PARTY BALANCES September 30, December 31, 2022 2021 Deferred revenue to a related party $ 111,011 $ - Accrued interest to a related party 145,508 147,768 For the three and nine months ended September 30, 2022 and 2021, we had the following related party transactions SCHEDULE OF RELATED PARTY TRANSACTIONS 2022 2021 2022 2021 For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Net sales to a related party $ 84,580 $ - $ 154,966 $ - Bad debt expense (recovery) - related party (21,799 ) (35,000 ) - 38,000 Rental income from a related party 10,000 - 10,000 - Interest expense to a related party 4,272 4,504 12,740 13,881 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Sep. 30, 2022 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | 14. SUBSEQUENT EVENTS During October 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 57,500 7,500 0.0006 On October 27, 2022, the promissory note of $ 199,000 199,000 60.73 |
BASIS OF PRESENTATION AND SUM_2
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Organization | Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® |
Basis of Presentation and Consolidation | Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K from which the accompanying condensed consolidated balance sheet dated December 31, 2021 was derived. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. |
Liquidity and Going Concern | Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $ 76,784,098 15,686,016 15,609,507 There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. |
Impact of COVID-19 on our Operations | Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $ 64,895 150,000 The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. |
Use of Estimates | Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. |
Revenue from Contracts with Customers | Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. |
Accounting for Shipping and Handling Costs | Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. |
Accounts Receivable and Allowance for Doubtful Accounts | Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No |
Inventories | Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. We classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at September 30, 2022 and December 31, 2021, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $ 0 48,000 294,162 |
Financial Instruments and Concentration of Credit Risk | Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended September 30, 2022, one customer accounted for 77 10 70 25 100 |
Operating Lease Right-of-Use Asset and Liability | Operating Lease Right-of-Use Asset and Liability The Company accounts for leases in accordance with Accounting Standards Update (“ASU”) 2016-02, Leases In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. |
Derivative Financial Instruments | Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to other income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. |
Convertible Debt | Convertible Debt For convertible debt that was issued before the adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity that did not contain an embedded derivative that required bifurcation, the conversion feature was evaluated to determine if the rate of conversion was below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt was recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt was recorded net of the discount for the BCF. The discount was amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. |
The Fair Value Measurement Option | The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging |
Derivative Accounting for Convertible Debt and Options and Warrants | Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, Derivatives and Hedging Embedded Derivatives |
Property and Equipment | Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 7 |
Long-Lived Assets | Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. |
Income Taxes | Income Taxes The Company recorded no |
Related Party Transactions | Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount (See Note 13). |
Stock-Based Compensation | Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation |
Net Income (Loss) Per Share | Net Income (Loss) Per Share Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share SCHEDULE OF NET INCOME (LOSS) PER SHARE 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Basic and diluted numerator: Net income (loss) - basic $ 577,229 $ 15,433,385 $ 4,944,891 $ (15,264,552 ) Effect of dilutive securities: Change in fair value of convertible notes (730,917 ) (2,595,948 ) (805,027 ) - Interest on convertible debt 61,313 91,454 213,995 - Net income (loss) - diluted $ (92,375 ) $ 12,928,891 $ 4,353,859 $ (15,264,552 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 7,592,286,997 7,289,196,290 7,471,152,031 7,201,163,176 Effect of dilutive securities: Convertible debt 8,005,326,919 5,380,857,096 7,633,625,439 - Options and warrants - - - - Weighted-average common shares outstanding - diluted (1) 15,597,613,916 12,670,053,386 15,104,777,470 7,201,163,176 Net income (loss) per share - basic and diluted $ (0.00 ) $ 0.00 $ 0.00 $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares. The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because for the three months ended September 30, 2022 and 2021, the exercise prices of the options and warrants were greater than the average market price of the common shares: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - - Convertible notes payable - - Total 447,014,285 108,175,000 The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because (1) for the nine months ended September 30, 2022, the exercise prices of the options and warrants were greater than the average market price of the common shares and (2) for the nine months ended September 30, 2021, the effect of including these potential shares was antidilutive due to a net loss: September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - 1,201,380,692 Convertible notes payable - 4,434,302,953 Total 447,014,285 5,743,858,645 |
Recent Adopted Accounting Pronouncements | Recent Adopted Accounting Pronouncements As of January 1, 2022, the Company adopted ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity As of January 1, 2022, the Company adopted ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. The adoption did not have a material effect on the accompanying consolidated financial statements. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. |
BASIS OF PRESENTATION AND SUM_3
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
SCHEDULE OF NET INCOME (LOSS) PER SHARE | SCHEDULE OF NET INCOME (LOSS) PER SHARE 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Basic and diluted numerator: Net income (loss) - basic $ 577,229 $ 15,433,385 $ 4,944,891 $ (15,264,552 ) Effect of dilutive securities: Change in fair value of convertible notes (730,917 ) (2,595,948 ) (805,027 ) - Interest on convertible debt 61,313 91,454 213,995 - Net income (loss) - diluted $ (92,375 ) $ 12,928,891 $ 4,353,859 $ (15,264,552 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 7,592,286,997 7,289,196,290 7,471,152,031 7,201,163,176 Effect of dilutive securities: Convertible debt 8,005,326,919 5,380,857,096 7,633,625,439 - Options and warrants - - - - Weighted-average common shares outstanding - diluted (1) 15,597,613,916 12,670,053,386 15,104,777,470 7,201,163,176 Net income (loss) per share - basic and diluted $ (0.00 ) $ 0.00 $ 0.00 $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares. |
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE | The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because for the three months ended September 30, 2022 and 2021, the exercise prices of the options and warrants were greater than the average market price of the common shares: SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - - Convertible notes payable - - Total 447,014,285 108,175,000 The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because (1) for the nine months ended September 30, 2022, the exercise prices of the options and warrants were greater than the average market price of the common shares and (2) for the nine months ended September 30, 2021, the effect of including these potential shares was antidilutive due to a net loss: September 30, 2022 September 30, 2021 Options and warrants 447,014,285 108,175,000 Convertible notes payable at fair value - 1,201,380,692 Convertible notes payable - 4,434,302,953 Total 447,014,285 5,743,858,645 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Short-Term Debt [Line Items] | |
SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE | The following table summarizes our financial instruments measured at fair value at September 30, 2022 and December 31, 2021: SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 200,103 $ - $ - $ 200,103 Derivative liabilities $ 4,897,066 $ - $ 4,897,066 $ - Convertible notes at fair value $ 1,745,305 $ - $ - $ 1,745,305 Total Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2021 Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 710,585 $ - $ - $ 710,585 Derivative liabilities $ 9,826,759 $ - $ 9,826,759 $ - Convertible notes at fair value $ 2,855,709 $ - $ - $ 2,855,709 |
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS | The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the nine months ended September 30, 2022 and the year ended December 31, 2021: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description September 30, 2022 December 31, 2021 Beginning balance $ 710,585 $ 189,543 Purchases, issuances, and settlements 100,000 590,885 Day one loss on value of hybrid instrument (1) Repayments in cash Conversion to common stock Total gain included in earnings (1) (1) (610,482 ) (69,843 ) Ending balance $ 200,103 $ 710,585 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS | The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at September 30, 2022 and December 31, 2021: SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS Conversion Price - Lower of Fixed Price or Percentage of VWAP for Look-back Period Debenture Face Amount Interest Rate Default Interest Rate Discount Rate Anti-Dilution Adjusted Price % of stock price for look-back period Look-back Period September 30, 2022 $ 711,446 8 10 20 24 N/A $ 0.00040 0.00048 50 60 3 25 December 31, 2021 $ 762,446 8 10 20 24 N/A $ 0.00050 0.00097 50 60 3 25 |
Convertible Notes Payable [Member] | |
Short-Term Debt [Line Items] | |
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS | SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description September 30, 2022 December 31, 2021 Beginning balance $ 2,855,709 $ 1,832,439 Purchases and issuances - 132,000 Day one loss on value of hybrid instrument (1) (1) - 2,042,612 Loss (gain) from change in fair value (1) (1) (1,029,404 ) 1,233,538 Repayments in cash (45,000 ) (40,480 ) Conversion to common stock (36,000 ) (2,344,399 ) Ending balance $ 1,745,305 $ 2,855,709 (1) The losses (gains) related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES (Tables)
INVENTORIES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Inventory Disclosure [Abstract] | |
SCHEDULE OF INVENTORIES | Inventories are valued at the lower of cost or net realizable value on an average cost basis. At September 30, 2022 and December 31, 2021, inventories were as follows: SCHEDULE OF INVENTORIES September 30, 2022 December 31, 2021 Raw Materials $ 131,005 $ 126,349 Finished Goods 8,721 3,820 Total Inventories 139,726 130,169 Less: Long-term inventory (90,380 ) (98,880 ) Current portion $ 49,346 $ 31,289 |
PROPERTY AND EQUIPMENT (Tables)
PROPERTY AND EQUIPMENT (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Property, Plant and Equipment [Abstract] | |
SCHEDULE OF PROPERTY AND EQUIPMENT | Property and equipment consists of the following at September 30, 2022 and December 31, 2021: SCHEDULE OF PROPERTY AND EQUIPMENT September 30, 2022 December 31, 2021 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 162,557 104,564 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 324,879 266,886 Less: Accumulated depreciation (239,273 ) (222,185 ) Property and equipment, net $ 85,606 $ 44,701 |
DEBTS (Tables)
DEBTS (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
SCHEDULE OF DEBT | Debts consist of the following at September 30, 2022 and December 31, 2021: SCHEDULE OF DEBT September 30, 2022 December 31, 2021 Notes payable – Unrelated third parties (Net of discount of $ 19,106 0 $ 1,285,287 $ 1,135,257 Convertible notes payable – Unrelated third parties (Net of discount of $ 183,570 283,429 4,609,567 3,751,760 Convertible notes payable, at fair value (4) 1,745,305 2,855,709 Other advances from an unrelated third party (5) 225,000 225,000 SBA notes payable(6) 149,900 149,900 Ending balances 8,015,059 8,117,626 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (4,707 ) (369,401 ) Less: Long-term portion- SBA notes payable (146,970 ) (146,970 ) Current portion $ 7,863,382 $ 7,600,446 |
SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT | SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT Years Amount 2022(2 months remaining) $ 525 2023 3,222 2024 3,345 2025 3,472 2026 3,605 Thereafter 135,731 149,900 Less: Long-term portion - SBA notes payable (146,970 ) Current portion $ 2,930 |
STOCK WARRANTS (Tables)
STOCK WARRANTS (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
SCHEDULE OF WARRANTS ISSUED | SCHEDULE OF WARRANTS ISSUED Month of Issuance Number of Warrants Month of Expiration August, 2020 92,100,000 August, 2022 October, 2020 36,300,000 October, 2022 |
SUMMARY OF WARRANTS OUTSTANDING | A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2021 and the nine months ended September 30, 2022: SUMMARY OF WARRANTS OUTSTANDING Number Of Weighted Balance December 31, 2020 202,775,000 $ 0.0017 Exercised - - Issued 410,403,571 0.0014 Expired (166,475,000 ) 0.0015 Balance December 31, 2021 446,703,571 $ 0.0017 Exercised - - Issued 164,285,714 0.0020 Expired (163,975,000 ) 0.0014 Balance September 30, 2022 447,014,285 $ 0.0019 |
SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING | The following table summarizes information about fixed-price warrants outstanding as of September 30, 2022 and December 31, 2021 : SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price September 30, 2022 $ 0.001 0.002 447,014,285 0.30 $ 0.0019 December 31, 2021 $ 0.001 0.002 446,703,571 0.67 $ 0.0017 |
ACCRUED EXPENSES (Tables)
ACCRUED EXPENSES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Payables and Accruals [Abstract] | |
SCHEDULE OF ACCRUED EXPENSES | Accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES September 30, 2022 December 31, Accrued consulting fees $ 161,550 $ 161,550 Accrued payroll taxes 227,912 215,543 Accrued interest 571,151 469,040 Accrued others 2,913 5,337 Total $ 963,526 $ 851,470 |
PREPAID EXPENSES (Tables)
PREPAID EXPENSES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Prepaid Expenses | |
SCHEDULE OF PREPAID EXPENSES | Prepaid expenses and other current assets consist of the following: SCHEDULE OF PREPAID EXPENSES September 30, 2022 December 31, Supplier advances for future purchases $ 339,162 $ 294,162 Reserve for supplier advances (294,162 ) (294,162 ) Net supplier advances 45,000 - Prepaid professional fees 72,650 65,650 Deferred stock compensation - 20,500 Total $ 117,650 $ 86,150 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION | SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION September 30, December 31, 2022 2021 Lease cost Operating lease cost $ 60,297 $ 80,396 Short-term lease cost - - Total lease cost $ 60,297 $ 80,396 Balance sheet information Operating ROU Assets $ 43,397 $ 93,811 Operating lease obligations, current portion 20,003 77,673 Operating lease obligations, non-current portion - - Total operating lease obligations $ 20,003 $ 77,673 Weighted average remaining lease term (in years) – operating leases 0.25 1 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows: Cash paid for amounts included in the measurement of operating lease liabilities $ 67,553 $ 95,846 |
SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE | Future minimum payments under these lease agreements are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 (Remaining three months) $ 20,270 Total future lease payments $ 20,270 Less imputed interest 267 Total $ 20,003 |
RELATED PARTY TRANSACTIONS (Tab
RELATED PARTY TRANSACTIONS (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Related Party Transactions [Abstract] | |
SCHEDULE OF RELATED PARTY BALANCES | As of September 30, 2022 and December 31, 2021, we had the following related party balances: SCHEDULE OF RELATED PARTY BALANCES September 30, December 31, 2022 2021 Deferred revenue to a related party $ 111,011 $ - Accrued interest to a related party 145,508 147,768 |
SCHEDULE OF RELATED PARTY TRANSACTIONS | For the three and nine months ended September 30, 2022 and 2021, we had the following related party transactions SCHEDULE OF RELATED PARTY TRANSACTIONS 2022 2021 2022 2021 For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Net sales to a related party $ 84,580 $ - $ 154,966 $ - Bad debt expense (recovery) - related party (21,799 ) (35,000 ) - 38,000 Rental income from a related party 10,000 - 10,000 - Interest expense to a related party 4,272 4,504 12,740 13,881 |
SCHEDULE OF NET INCOME (LOSS) P
SCHEDULE OF NET INCOME (LOSS) PER SHARE (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | ||
Accounting Policies [Abstract] | |||||
Net income (loss) - basic | $ 577,229 | $ 15,433,385 | $ 4,944,891 | $ (15,264,552) | |
Change in fair value of convertible notes | (730,917) | (2,595,948) | (805,027) | ||
Interest on convertible debt | 61,313 | 91,454 | 213,995 | ||
Net income (loss) - diluted | $ (92,375) | $ 12,928,891 | $ 4,353,859 | $ (15,264,552) | |
Weighted-average common shares outstanding - basic | 7,592,286,997 | 7,289,196,290 | 7,471,152,031 | 7,201,163,176 | |
Convertible debt | 8,005,326,919 | 5,380,857,096 | 7,633,625,439 | ||
Options and warrants | |||||
Weighted-average common shares outstanding - diluted | [1] | 15,597,613,916 | 12,670,053,386 | 15,104,777,470 | 7,201,163,176 |
Net income (loss) per share - basic and diluted | $ 0 | $ 0 | $ 0 | $ 0 | |
[1]Includes potential common shares that are in excess of authorized shares. |
SCHEDULE OF ANTIDILUTIVE SECURI
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 447,014,285 | 108,175,000 | 447,014,285 | 5,743,858,645 |
Options and Warrants [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 447,014,285 | 108,175,000 | 447,014,285 | 108,175,000 |
Convertible Notes Payable Fair Value [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 1,201,380,692 | |||
Convertible Notes Payable [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Total | 4,434,302,953 |
BASIS OF PRESENTATION AND SUM_4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
May 31, 2020 | Sep. 30, 2022 | Sep. 30, 2021 | Jun. 30, 2020 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2020 | |
Product Information [Line Items] | ||||||||||
Accumulated deficit | $ 76,784,098 | $ 76,784,098 | $ 81,728,989 | |||||||
Working capital | 15,686,016 | 15,686,016 | ||||||||
stockholders' deficit | 15,609,507 | $ 23,620,681 | 15,609,507 | $ 23,620,681 | 20,877,650 | $ 16,197,236 | $ 39,244,098 | $ 11,493,815 | ||
Allowance for doubtful account | 0 | 0 | 0 | |||||||
Change in reserve for supplier advances for purchases | 0 | 48,000 | ||||||||
Inventory valuation allowance | 294,162 | 294,162 | $ 294,162 | |||||||
Income tax expense | ||||||||||
Minimum [Member] | ||||||||||
Product Information [Line Items] | ||||||||||
Property and equipment estimated useful lives | 3 years | |||||||||
Maximum [Member] | ||||||||||
Product Information [Line Items] | ||||||||||
Property and equipment estimated useful lives | 7 years | |||||||||
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member] | ||||||||||
Product Information [Line Items] | ||||||||||
Concentration risk, percentage | 77% | 10% | 70% | 25% | ||||||
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member] | ||||||||||
Product Information [Line Items] | ||||||||||
Concentration risk, percentage | 100% | 100% | ||||||||
Economic Injury Disaster Loan Assistance Program [Member] | ||||||||||
Product Information [Line Items] | ||||||||||
Loan amount | $ 150,000 | |||||||||
SBA Loan Agreement [Member] | ||||||||||
Product Information [Line Items] | ||||||||||
Proceeds form loan | $ 64,895 |
SUMMARY OF FINANCIAL INSTRUMENT
SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Warrant liability | $ 200,103 | $ 710,585 |
Derivative liabilities | 4,897,066 | 9,826,759 |
Convertible notes at fair value | 1,745,305 | 2,855,709 |
Fair Value, Inputs, Level 1 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Warrant liability | ||
Derivative liabilities | ||
Convertible notes at fair value | ||
Fair Value, Inputs, Level 2 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Warrant liability | ||
Derivative liabilities | 4,897,066 | 9,826,759 |
Convertible notes at fair value | ||
Fair Value, Inputs, Level 3 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Warrant liability | 200,103 | 710,585 |
Derivative liabilities | ||
Convertible notes at fair value | $ 1,745,305 | $ 2,855,709 |
SUMMARY OF CHANGES IN FAIR VALU
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS (Details) - USD ($) | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2022 | Dec. 31, 2021 | ||
Short-Term Debt [Line Items] | |||
Beginning balance | $ 710,585 | $ 189,543 | |
Purchases and issuances | 100,000 | 590,885 | |
Loss (gain) from change in fair value (1) | [1] | (610,482) | (69,843) |
Ending balance | 200,103 | 710,585 | |
Convertible Notes Payable [Member] | |||
Short-Term Debt [Line Items] | |||
Beginning balance | 2,855,709 | 1,832,439 | |
Purchases and issuances | 132,000 | ||
Day one loss on value of hybrid instrument (1) | [2] | 2,042,612 | |
Repayments in cash | (45,000) | (40,480) | |
Conversion to common stock | (36,000) | (2,344,399) | |
Loss (gain) from change in fair value (1) | [2] | (1,029,404) | 1,233,538 |
Ending balance | $ 1,745,305 | $ 2,855,709 | |
[1]The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.[2]The losses (gains) related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
SUMMARY OF ASSUMPTIONS AND THE
SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS (Details) - Convertible Notes Payable [Member] | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 USD ($) Day $ / shares | Dec. 31, 2021 USD ($) Day $ / shares | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Face Amount | $ | $ 711,446 | $ 762,446 |
Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.00040 | $ 0.00050 |
Percentage of stock price for look-back period | 50% | 50% |
Look-back period | Day | 3 | 3 |
Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.00048 | $ 0.00097 |
Percentage of stock price for look-back period | 60% | 60% |
Look-back period | Day | 25 | 25 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Long-term debt, measurement input | 8 | 8 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Long-term debt, measurement input | 10 | 10 |
Measurement Input, Default Interest Rate [Member] | Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Long-term debt, measurement input | 0.20 | 0.20 |
Measurement Input, Default Interest Rate [Member] | Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Long-term debt, measurement input | 0.24 | 0.24 |
FAIR VALUE MEASUREMENTS (Detail
FAIR VALUE MEASUREMENTS (Details Narrative) | Sep. 30, 2022 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants and Rights Outstanding, Measurement Input | 2.79 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants and Rights Outstanding, Measurement Input | 3.92 |
Measurement Input, Price Volatility [Member] | Minimum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants and Rights Outstanding, Measurement Input | 411 |
SCHEDULE OF INVENTORIES (Detail
SCHEDULE OF INVENTORIES (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Raw Materials | $ 131,005 | $ 126,349 |
Finished Goods | 8,721 | 3,820 |
Total Inventories | 139,726 | 130,169 |
Less: Long-term inventory | (90,380) | (98,880) |
Current portion | $ 49,346 | $ 31,289 |
SCHEDULE OF PROPERTY AND EQUIPM
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] | ||
Total | $ 324,879 | $ 266,886 |
Less: Accumulated depreciation | (239,273) | (222,185) |
Property and equipment, net | 85,606 | 44,701 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 25,120 | 25,120 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 34,757 | 34,757 |
Lab Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 162,557 | 104,564 |
Telephone Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 12,421 | 12,421 |
Office Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 16,856 | 16,856 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | $ 73,168 | $ 73,168 |
PROPERTY AND EQUIPMENT (Details
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Property, Plant and Equipment [Abstract] | ||||
Depreciation expense | $ 5,898 | $ 2,793 | $ 17,088 | $ 6,178 |
DUE TO_FROM OFFICER (Details Na
DUE TO/FROM OFFICER (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Defined Benefit Plan Disclosure [Line Items] | |||||
Due to officers or stockholders, current | $ 61,439 | $ 61,439 | $ 199,726 | ||
Repayments of related party debt | 204,000 | $ 120,250 | |||
Proceeds from related party debt | 62,201 | 56,900 | |||
Accrued interest on the demand | 3,512 | 5,788 | 7,520 | ||
Accounts Receivable, Credit Loss Expense (Reversal) | (21,799) | $ (35,000) | 38,000 | ||
Accounts Receivable, Credit Loss Expense (Reversal) | 21,799 | 35,000 | $ (38,000) | ||
[custom:ProvisionForDoubtfulAccountsBadDebtRecovery] | $ 35,000 | ||||
Rik Deitsch [Member] | |||||
Defined Benefit Plan Disclosure [Line Items] | |||||
Due to officers or stockholders, current | $ 61,439 | $ 61,439 | $ 199,726 | ||
Debt instrument, interest rate, stated percentage | 4% | 4% | 4% | ||
Repayments of related party debt | $ 204,000 | $ 182,741 | |||
Proceeds from related party debt | 62,201 | $ 105,780 | |||
Accrued interest on the demand | $ 3,512 |
SCHEDULE OF DEBT (Details)
SCHEDULE OF DEBT (Details) - USD ($) | Sep. 30, 2022 | Aug. 31, 2022 | Dec. 31, 2021 |
Debt Disclosure [Abstract] | |||
Notes payable – Unrelated third parties (Net of discount of $19,106 and $0, respectively) (2) | $ 1,285,287 | $ 166,926 | $ 1,135,257 |
Convertible notes payable – Unrelated third parties (Net of discount of $183,570 and $283,429, respectively) (3) | 4,609,567 | 3,751,760 | |
Convertible notes payable, at fair value (4) | 1,745,305 | 2,855,709 | |
Other advances from an unrelated third party (5) | 225,000 | 225,000 | |
SBA notes payable(6) | 149,900 | 149,900 | |
Ending balances | 8,015,059 | 8,117,626 | |
Less: Long-term portion-Convertible Notes payable-Unrelated third parties | (4,707) | (369,401) | |
Less: Long-term portion- SBA notes payable | (146,970) | (146,970) | |
Current portion | $ 7,863,382 | $ 7,600,446 |
SCHEDULE OF DEBT (Details) (Par
SCHEDULE OF DEBT (Details) (Parenthetical) - USD ($) | Sep. 30, 2022 | Aug. 31, 2022 | Dec. 31, 2021 |
Short-Term Debt [Line Items] | |||
Debt instrument unamortized discount | $ 16,693 | ||
Note Payable [Member] | |||
Short-Term Debt [Line Items] | |||
Debt instrument unamortized discount | $ 19,106 | $ 0 | |
Convertible Notes Payable [Member] | |||
Short-Term Debt [Line Items] | |||
Debt instrument unamortized discount | $ 183,570 | $ 283,429 |
SCHEDULE OF FUTURE MINIMUM PRIN
SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Short-Term Debt [Line Items] | ||
Current portion | $ 7,863,382 | $ 7,600,446 |
PPP and EIDL Loan [Member] | ||
Short-Term Debt [Line Items] | ||
2022(2 months remaining) | 525 | |
2023 | 3,222 | |
2024 | 3,345 | |
2025 | 3,472 | |
2026 | 3,605 | |
Thereafter | 135,731 | |
Total | 149,900 | |
Less: Long-term portion - SBA notes payable | (146,970) | |
Current portion | $ 2,930 |
DEBTS (Details Narrative)
DEBTS (Details Narrative) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 5 Months Ended | 8 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jan. 02, 2022 USD ($) | Oct. 22, 2020 USD ($) | Feb. 28, 2019 USD ($) $ / shares shares | Feb. 15, 2019 USD ($) | Sep. 26, 2016 USD ($) | Aug. 02, 2011 USD ($) shares | Aug. 31, 2022 USD ($) $ / shares shares | May 31, 2022 USD ($) $ / shares shares | Feb. 28, 2022 USD ($) shares | Jan. 31, 2022 USD ($) $ / shares shares | Aug. 31, 2021 USD ($) $ / shares shares | Apr. 30, 2021 USD ($) shares | Mar. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) $ / shares | Nov. 30, 2020 USD ($) shares | Oct. 31, 2020 USD ($) | Sep. 30, 2020 USD ($) shares | Aug. 31, 2020 USD ($) | Jul. 31, 2020 USD ($) $ / shares shares | Jun. 30, 2020 USD ($) | May 31, 2020 USD ($) | Apr. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) shares | Dec. 31, 2019 USD ($) $ / shares shares | Nov. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) shares | May 31, 2019 USD ($) shares | Feb. 28, 2019 USD ($) $ / shares | Jan. 31, 2019 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Nov. 30, 2017 USD ($) shares | Oct. 31, 2017 USD ($) | Jul. 31, 2017 USD ($) | Jun. 30, 2017 USD ($) | May 31, 2017 USD ($) Day | Apr. 30, 2017 USD ($) shares | Oct. 31, 2016 USD ($) | Aug. 31, 2016 USD ($) shares | May 31, 2016 USD ($) | Apr. 30, 2016 USD ($) | Aug. 31, 2013 USD ($) | Jun. 30, 2012 USD ($) | Feb. 29, 2020 USD ($) shares | Sep. 30, 2022 USD ($) $ / shares | Mar. 31, 2022 USD ($) $ / shares | Dec. 31, 2021 USD ($) $ / shares | Sep. 30, 2021 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) $ / shares | Mar. 31, 2020 USD ($) | Mar. 31, 2012 USD ($) | Jun. 30, 2021 USD ($) shares | Nov. 01, 2021 | Sep. 30, 2022 USD ($) Day $ / shares | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) Day $ / shares shares | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) $ / shares | Dec. 31, 2012 USD ($) | Dec. 31, 2010 USD ($) | Jun. 30, 2022 USD ($) $ / shares | Nov. 30, 2021 USD ($) $ / shares | Aug. 31, 2018 USD ($) | Jul. 31, 2018 USD ($) | Jun. 30, 2016 USD ($) | Mar. 31, 2016 USD ($) | Dec. 31, 2011 USD ($) | |
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 145,508 | $ 147,768 | $ 145,508 | $ 147,768 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 166,926 | 1,285,287 | 1,135,257 | 1,285,287 | 1,135,257 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 16,693 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payament | $ 3,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments for rent | $ 5,000 | 10,000 | 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | shares | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, value | $ 500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 404,549 | $ 232,117 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 4,609,567 | 3,751,760 | 4,609,567 | 3,751,760 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | 17,250 | 710,000 | 1,976,560 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | $ 13,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | 3,000 | $ 16,693 | 60,994 | 65,028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued | 36,000 | 2,344,399 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (56,339) | (151,559) | (485,836) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other expense | 500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes at fair value | 1,745,305 | 2,855,709 | 1,745,305 | 2,855,709 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other advances from an unrelated third party | $ 225,000 | $ 225,000 | 225,000 | $ 225,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long term debt | $ 251,340 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants at an exercise price | $ / shares | $ 0.002 | $ 0.002 | $ 0.002 | $ 0.002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants at an exercise price | $ / shares | 0.001 | 0.001 | 0.001 | 0.001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | 0.00048 | 0.00097 | $ 0.00048 | $ 0.00097 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | Day | 25 | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60% | 60% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | $ 0.00040 | $ 0.00050 | $ 0.00040 | $ 0.00050 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | Day | 3 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 50% | 50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 37,917 | $ 37,917 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, shares issued | shares | 750,000,000 | 750,000,000 | 500,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument Unamortized Discount Premium | $ 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 4,688 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Stock | shares | 16,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 240,000 | $ 240,000 | $ 240,000 | $ 240,000 | $ 240,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Loss | 240,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 100,000 | $ 100,000 | $ 175,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument amount | $ 275,000 | 275,000 | $ 425,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, description | The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,000,000 | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | $ 0.0005 | $ 0.0005 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 275,000 | 275,000 | 275,000 | 275,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Eight Tranches [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 20,199 | 372,374 | $ 20,199 | $ 372,374 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 27,000 | 27,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 132,000 | 132,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 11,412 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | 45,000 | 40,480 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Loss | 2,042,612 | 2,042,612 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
University Centre West Ltd [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments for rent | $ 55,410 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Related Party Ten [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 74,000 | 74,000 | 74,000 | 74,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Related Party Elven [Member] | Note Payable Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 18,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument Unamortized Discount Premium | 3,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Receipts Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 87,000 | 87,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-related Party [Member] | Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 12,629 | 12,629 | 12,629 | 12,629 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 20% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | May 04, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | 16,728 | 14,834 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 64,000 | 48,929 | 70,418 | 48,929 | 70,418 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | Day | 20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-related Party [Member] | Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 8% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Holder [Member] | Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 509,301 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 234,417 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Loss | 286,969 | 286,969 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Related Party Twenty Two [Member] | Convertible Notes Payable Five [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 17,829 | 17,829 | 17,829 | 17,829 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unrelated Third Party [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other advances from an unrelated third party | 225,000 | 225,000 | 225,000 | 225,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unrelated Third Party [Member] | Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 37,917 | 88,917 | 37,917 | 88,917 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 75,834 | 355,668 | 75,834 | 355,668 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brewer and Associates Consulting, LLC [Member] | Non Related Party Twenty [Member] | Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 20,000 | 20,000 | 20,000 | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | 24,217 | 21,183 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 55% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 80,395 | 84,768 | 80,395 | 84,768 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 19,106 | 0 | 19,106 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 6,541 | 5,783 | 6,541 | 5,783 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 2% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 83,434 | 74,334 | 83,434 | 74,334 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 50,000 | 50,000 | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 75,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | shares | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 2% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 76,634 | 67,534 | 76,634 | 67,534 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 50,000 | 50,000 | 50,000 | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Four [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 2% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 333,543 | 333,543 | 333,543 | 333,543 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 333,543 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 248,378 | 187,673 | 248,378 | 187,673 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Four [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 5,895 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued, reverse stock splits | shares | 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | shares | 20,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, value | $ 6,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Five [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 15,900 | 1,371 | 1,371 | 1,371 | 1,371 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 60,000 | 15,000 | 15,000 | 15,000 | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 75,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | $ 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Six [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 2% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 72,934 | 63,834 | 72,934 | 63,834 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Seven [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 6,698 | 5,750 | 6,698 | 5,750 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 12,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eight [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 15% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 33,874 | 33,874 | 33,874 | 33,874 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | 33,874 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt settlement amount | $ 130,401 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | 14,376 | 44,478 | 42,698 | $ 34,976 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eight [Member] | One Unrelated Third Parties [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | $ 130,401 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eight [Member] | Two Unrelated Third Parties [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | $ 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Nine [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 50,000 | 50,000 | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Twelve [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | shares | 125,000,000 | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, value | $ 87,500 | $ 32,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement of debt | $ 37,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, shares issued | shares | 36,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument unamortized discount | $ 14,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 74,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 183,619 | 60,000 | 60,000 | 60,000 | 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 16,693 | 16,693 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | $ 183,619 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | shares | 10,000,000 | 20,866,250 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, value | $ 10,000 | $ 54,252 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Origination fees | 29,685 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Stock | shares | 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 10,000 | 114,000 | 37,559 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note [Member] | Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 75,000 | 55,900 | 55,900 | 55,900 | 55,900 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 15,900 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 60,000 | 111,800 | 156,000 | 111,800 | 156,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Loss | 75,900 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note [Member] | Non Related Party Ten [Member] | Note Payable Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 70,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 4,609,567 | 3,751,760 | 4,609,567 | 3,751,760 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 183,570 | 283,429 | 183,570 | 283,429 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument unamortized discount | 183,570 | 283,429 | 183,570 | 283,429 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 123,813 | 91,455 | 388,994 | 213,924 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 183,570 | 283,430 | 183,570 | 283,430 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | 3,125,268 | 3,125,268 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Unrelated Third Party [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 286,550 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 26,050 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 0 | 13,070 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Thirteen [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 9,200 | $ 62,950 | 62,950 | 62,950 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | shares | 800,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, value | $ 87,100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | 55,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 28,421 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | 618,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 255,655 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Excerice of price | shares | 128,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants at an exercise price | $ / shares | $ 0.001 | $ 0.001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value adjustment of warrants | $ 36,300,000 | $ 92,100,000 | 541 | 195,178 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price | $ / shares | $ 0.0003 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price | $ / shares | $ 0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 287,400 | $ 268,200 | 287,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 5,000 | 15,000 | $ 15,000 | 53,600 | $ 7,500 | $ 5,000 | 70,350 | $ 112,725 | $ 112,725 | 70,350 | 53,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | 22,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, value | 700 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 115,000 | 115,000 | $ 57,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 83,720 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 55,000 | 358,800 | 864,225 | 555,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 1,276,902 | 1,276,902 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | $ 0.0005 | $ 0.0005 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 101,448 | 101,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Excerice of price | shares | 222,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | Valuation Technique, Option Pricing Model [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 100,000 | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Excerice of price | shares | 164,285,714 | 164,285,714 | 71,875,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants at an exercise price | $ / shares | $ 0.002 | $ 0.002 | $ 0.002 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value adjustment of warrants | 0 | 106,032 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | Warrant [Member] | Valuation Technique, Option Pricing Model [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 15,000 | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value adjustment of warrants | 93,748 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Two Convertible Notes Payable One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 6,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Two Convertible Notes Payable Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 17,370 | 17,370 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 14,500 | 14,500 | $ 14,500 | $ 14,500 | 14,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 17,370 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 174,500 | $ 174,500 | $ 174,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price | $ / shares | $ 0.0002 | $ 0.000275 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price | $ / shares | $ 0.0008 | $ 0.0002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 736,180 | $ 736,180 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Stock | shares | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | Aug. 29, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 228,563 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 93,609 | $ 50,000 | $ 46,800 | 93,609 | 46,800 | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | 539,351 | $ 717,667 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price | $ / shares | $ 0.0003 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price | $ / shares | $ 0.002 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Three [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 7,500 | $ 7,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Four [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 22,500 | 22,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | 172,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Four [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 150,000 | $ 150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Excerice of price | shares | 246,428,571 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants at an exercise price | $ / shares | $ 0.002 | $ 0.002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value adjustment of warrants | 105,814 | $ 409,374 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Five [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 15,433 | $ 22,677 | 15,433 | 22,677 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 12% | 12% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 513 | 793 | $ 1,756 | 1,951 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 30,000 | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | 7,323 | 7,244 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payament | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | shares | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Six [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fair Value | 222,500 | $ 15,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | 8,500 | $ 6,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | shares | 11,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, value | $ 104,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement of debt | 114,000 | 11,200 | 98,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | 12,000 | 11,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | 4,500 | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued | 108,500 | $ 4,000 | 6,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Seven [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 183,619 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 108,500 | 166,926 | $ 5,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 16,693 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | $ 0.002 | $ 0.002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eleven [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 16,693 | $ 16,693 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fair Value | $ 54,252 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | $ 108,500 | $ 166,926 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | $ 0.002 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on settlement of debt | $ 37,559 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eleven [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | shares | 20,866,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Four [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate Terms | We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debtentures [Member] | Convertible Notes Payable Four [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 50,000 | $ 50,000 | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | 42,367 | 33,490 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 167,940 | 202,491 | 167,940 | 202,491 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debtentures [Member] | Non-related Party [Member] | Convertible Notes Payable Four [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 8% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Loss | $ 46,734 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debtentures [Member] | Note Holder [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | 82,022 | 32,657 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 714,044 | 946,639 | 714,044 | 946,639 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debtentures [Member] | Non Related Party Twenty Two [Member] | Convertible Notes Payable Five [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 20,000 | 20,000 | 20,000 | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 8% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | 16,500 | 12,923 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 66,363 | 79,815 | 66,363 | 79,815 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restatement of Promissory Notes [Member] | Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | 75,900 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Stock | shares | 100,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 20,000 | $ 75,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, restricted stock value | 140,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | $ 17,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, value | $ 500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Stock | shares | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note [Member] | Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fair Value | 480,000 | 960,000 | 480,000 | 960,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PPP and EIDL Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Interest | 13,124 | 8,906 | 13,124 | 8,906 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan Agreement [Member] | Note Payable One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 9 months | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement Agreement [Member] | Non Related Party Elven [Member] | Note Payable Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | 18,000 | 18,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | 2,000 | 2,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 175,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | $ 350,000 | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payament | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Penalty for non-payment | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sale of stock, shares | shares | 142,858 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued, reverse stock splits | shares | 5,714,326 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from settlement | $ 450,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from initial legal settlement | 350,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Penalties on legal settlement | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member] | Note Payable Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 2,675 | 2,675 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 130,977 | 130,977 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | $ 10,000 | 68,023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement Agreement [Member] | Southridge Partners LLP [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business combination, consideration transferred | $ 281,772 | $ 281,772 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Receipts Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 16,431 | 16,431 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Receipts Agreement [Member] | Note Payable Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 31,730 | 31,730 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt | 38,839 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Receipts Agreement [Member] | Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 12,369 | 885 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Agreement [Member] | Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fair Value | $ 36,000 | $ 2,344,399 | $ 2,344,399 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Stock | shares | 12,000,000 | 240,350,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, restricted stock value | $ 6,000 | $ 120,175 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBA Loan Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 3.75% | 3.75% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 731 | 731 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding notes payable | $ 150,000 | $ 150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SBA Loan Agreement [Member] | PPP [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 1% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, description | During May 2020, we entered into a two-year loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $64,895 with an annual interest rate of one percent (1%), with a term of twenty-four (24) months, whereby a portion of the loan proceeds have been used for certain labor costs, office rent costs and utilities, which may be subject to a loan forgiveness, pursuant to the terms of the SBA/PPP program. We used the proceeds primarily for payroll costs. The entire loan was forgiven in November 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long term debt | $ 64,895 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Director [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 40,000 | 15,000 | 10,000 | $ 40,000 | 10,000 | 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Director [Member] | Loan Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate Terms | interest calculated at 10% for the first month plus 12% after 30 days from funding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 12% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 145,508 | 147,768 | 145,508 | 147,768 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 4,272 | $ 4,504 | 12,740 | $ 13,881 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Former Director [Member] | Two Promissory Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 101,818 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 12% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 21,023 | 60,037 | 51,856 | 60,037 | 51,856 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 91,156 | $ 91,156 | $ 91,156 | $ 91,156 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of debt | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fair Value | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | $ 104,000 | $ 88,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of debt | $ 15,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt settlement amount | $ 88,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement, description | The remaining principal balance of $91,156 and accrued interest of $60,037 is being disputed in court and negotiation for settlement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-related Party [Member] | Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Rate | 63.76% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Due from related parties | $ 199,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Origination fees | $ 4,975 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 850 | $ 2,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Receipts Agreement [Member] | Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Due from related parties | 87,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unrelated Third Parties [Member] | Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 264,500 | 172,500 | 264,500 | 379,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 34,500 | $ 22,500 | $ 34,500 | $ 49,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unrelated Third Parties [Member] | Convertible Notes Payable [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | $ 0.0006 | $ 0.0008 | $ 0.0006 | $ 0.0008 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unrelated Third Parties [Member] | Convertible Notes Payable [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion Price | $ / shares | $ 0.0005 | $ 0.0005 | $ 0.0005 | $ 0.0006 |
STOCKHOLDERS_ DEFICIT (Details
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 5 Months Ended | 9 Months Ended | ||||||||||||||||||||
Nov. 15, 2021 | Oct. 30, 2017 | Aug. 31, 2022 | May 31, 2022 | Feb. 28, 2022 | Aug. 31, 2021 | Jul. 31, 2021 | Apr. 30, 2021 | Mar. 31, 2021 | Jul. 31, 2020 | Sep. 30, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Jun. 30, 2022 | Jan. 31, 2022 | Dec. 31, 2021 | Nov. 30, 2021 | Nov. 18, 2021 | Nov. 17, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Feb. 28, 2019 | |
Class of Stock [Line Items] | ||||||||||||||||||||||||
Common stock, shares authorized | 12,000,000,000 | 12,000,000,000 | 12,000,000,000 | 12,000,000,000 | 8,000,000,000 | |||||||||||||||||||
Stock issued during period, shares, new issues | 500,000 | |||||||||||||||||||||||
Share Price | $ 0.133 | $ 0.133 | ||||||||||||||||||||||
Debt instrument unamortized discount | $ 16,693 | |||||||||||||||||||||||
Notes payable | 166,926 | $ 1,285,287 | $ 1,285,287 | $ 1,135,257 | ||||||||||||||||||||
Stock issued during period, value, new issues | $ 500 | |||||||||||||||||||||||
Gain (Loss) on extinguishment of debt | $ (56,339) | (151,559) | $ (485,836) | |||||||||||||||||||||
Stock issued | 36,000 | 2,344,399 | ||||||||||||||||||||||
Issuance of common stock in exchange for services to consultants | 117,000 | 150,000 | ||||||||||||||||||||||
Stock based compensation | 0 | $ 64,750 | 20,500 | $ 66,195 | ||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Issuance of common stock in exchange for services to consultants, shares | 20,000,000 | 25,000,000 | ||||||||||||||||||||||
Issuance of common stock in exchange for services to consultants | $ 20,000 | $ 25,000 | ||||||||||||||||||||||
Promissory Note [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Stock issued during period, shares, new issues | 10,000,000 | 20,866,250 | ||||||||||||||||||||||
Stock issued during period, restricted stock shares | 10,000,000 | |||||||||||||||||||||||
Debt instrument unamortized discount | $ 16,693 | $ 16,693 | ||||||||||||||||||||||
Notes payable | $ 183,619 | 60,000 | 60,000 | 60,000 | ||||||||||||||||||||
Stock issued during period, value, new issues | 10,000 | $ 54,252 | ||||||||||||||||||||||
Gain (Loss) on extinguishment of debt | 10,000 | $ 114,000 | 37,559 | |||||||||||||||||||||
Repayment of debt | $ 183,619 | |||||||||||||||||||||||
Convertible Notes Payable Seven [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Debt instrument unamortized discount | 16,693 | |||||||||||||||||||||||
Notes payable | 108,500 | $ 166,926 | $ 5,750 | |||||||||||||||||||||
Convertible Notes Payable Two [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Debt instrument unamortized discount | $ 15,000 | $ 7,500 | $ 70,350 | $ 112,725 | $ 70,350 | $ 15,000 | $ 53,600 | $ 5,000 | ||||||||||||||||
Notes payable | $ 287,400 | $ 268,200 | ||||||||||||||||||||||
Stock issued during period, value, new issues | 700 | |||||||||||||||||||||||
Repayment of debt | $ 22,000 | |||||||||||||||||||||||
Convertible Notes Payable Two [Member] | Common Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Excerice of price | 222,500,000 | |||||||||||||||||||||||
Convertible Notes Payable Six [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Stock issued during period, shares, new issues | 11,000,000 | |||||||||||||||||||||||
Stock issued during period, value, new issues | $ 104,500 | |||||||||||||||||||||||
Stock issued | $ 108,500 | $ 4,000 | $ 6,000 | |||||||||||||||||||||
Debt instrument fair value | $ 222,500 | $ 15,200 | ||||||||||||||||||||||
Convertible Promissory Note [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Stock issued during period, restricted stock shares | 500,000 | |||||||||||||||||||||||
Stock issued during period, value, new issues | $ 500 | |||||||||||||||||||||||
Repayment of debt | $ 17,250 | |||||||||||||||||||||||
Convertible Notes Payable [Member] | Convertible Promissory Note [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Debt instrument fair value | 480,000 | 480,000 | $ 960,000 | |||||||||||||||||||||
Convertible Notes Payable [Member] | Note Agreement [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Stock issued during period, restricted stock shares | 12,000,000 | 240,350,000 | ||||||||||||||||||||||
Stock issued during period, restricted stock value | $ 6,000 | $ 120,175 | ||||||||||||||||||||||
Debt instrument fair value | 36,000 | $ 2,344,399 | ||||||||||||||||||||||
Note Holder [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Fair value of debt converted | $ 36,000 | |||||||||||||||||||||||
Note Holder [Member] | Restricted Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Stock issued during period, restricted stock shares | 12,000,000 | |||||||||||||||||||||||
Consultant [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Issuance of common stock in exchange for services to consultants, shares | 5,000,000 | |||||||||||||||||||||||
Issuance of common stock in exchange for services to consultants | $ 41,000 | |||||||||||||||||||||||
Stock based compensation | $ 0 | $ 20,500 | ||||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 20,000,000 | |||||||||||||||||||||||
Stock issued during period, shares, new issues | 3,000,000 | |||||||||||||||||||||||
Series A Preferred Stock [Member] | Board of Directors [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Stock issued during period shares exchanged | 3,000,000 | |||||||||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 20,000,000 | 20,000,000 | 20,000,000 | |||||||||||||||||||||
Stock issued during period, shares, new issues | 12,000,000 | |||||||||||||||||||||||
Preferred stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||||||||||||||
Preferred stock liquidation value | $ 0 | $ 0 | $ 0 | |||||||||||||||||||||
Shares issued | 9,000,000 | |||||||||||||||||||||||
Accrued salaries | $ 540,000 | |||||||||||||||||||||||
Series B Preferred Stock [Member] | Board of Directors [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Stock issued during period shares exchanged | 3,000,000 |
SCHEDULE OF WARRANTS ISSUED (De
SCHEDULE OF WARRANTS ISSUED (Details) - shares | 1 Months Ended | |
Oct. 31, 2020 | Aug. 31, 2020 | |
Share-Based Payment Arrangement [Abstract] | ||
Number of Warrants | 36,300,000 | 92,100,000 |
Month of Expiration | October, 2022 | August, 2022 |
SUMMARY OF WARRANTS OUTSTANDING
SUMMARY OF WARRANTS OUTSTANDING (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Weighted Average Exercise Price, Warrants, Beginning | $ 0.0017 | |
Weighted Average Exercise Price, Warrants, Ending | $ 0.0019 | $ 0.0017 |
Warrant [Member] | ||
Number of warrants outstanding, Beginning | 446,703,571 | 202,775,000 |
Weighted Average Exercise Price, Warrants, Beginning | $ 0.0017 | $ 0.0017 |
Number of warrants, Exercised | ||
Weighted Average Exercise Price, Warrants, Exercised | ||
Number of warrants, Issued | 164,285,714 | 410,403,571 |
Weighted Average Exercise Price, Warrants, Issued | $ 0.0020 | $ 0.0014 |
Number of warrants, Expired | (163,975,000) | (166,475,000) |
Weighted Average Exercise Price, Warrants, Expired | $ 0.0014 | $ 0.0015 |
Number of warrants outstanding, Ending | 447,014,285 | 446,703,571 |
Weighted Average Exercise Price, Warrants, Ending | $ 0.0019 | $ 0.0017 |
SUMMARY OF FIXED PRICE WARRANTS
SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Weighted Average Number Outstanding | 447,014,285 | 446,703,571 |
Weighted Average Contractual Life | 3 months 18 days | 8 months 1 day |
Weighted Average Exercise Price | $ 0.0019 | $ 0.0017 |
Minimum [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Exercise Price | 0.001 | 0.001 |
Maximum [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Exercise Price | $ 0.002 | $ 0.002 |
STOCK WARRANTS (Details Narrati
STOCK WARRANTS (Details Narrative) - USD ($) | 2 Months Ended | 5 Months Ended | 9 Months Ended | 12 Months Ended | |||
Dec. 31, 2020 | May 31, 2022 | Sep. 30, 2022 | Dec. 31, 2021 | Aug. 31, 2022 | Oct. 31, 2020 | Aug. 31, 2020 | |
Short-Term Debt [Line Items] | |||||||
Debt instrument unamortized discount | $ 16,693 | ||||||
Two Convertible Notes Payable [Member] | |||||||
Short-Term Debt [Line Items] | |||||||
Warrants, fair value | $ 0 | $ 106,032 | |||||
Two Convertible Notes Payable [Member] | |||||||
Short-Term Debt [Line Items] | |||||||
Debt instrument unamortized discount | $ 7,500 | ||||||
Warrants price | $ 0.002 | ||||||
Equity instruments other than options, grants in period | 71,875,000 | ||||||
Long-term debt, gross | $ 57,500 | ||||||
Three Convertible Notes Payable [Member] | |||||||
Short-Term Debt [Line Items] | |||||||
Debt instrument, face amount | 172,500 | ||||||
Debt instrument unamortized discount | $ 22,500 | ||||||
Warrants price | $ 0.002 | ||||||
Warrants, fair value | 105,814 | $ 409,374 | |||||
Excerice of price | 246,428,571 | ||||||
Four Convertible Notes Payable [Member] | |||||||
Short-Term Debt [Line Items] | |||||||
Debt instrument, face amount | $ 115,000 | ||||||
Debt instrument unamortized discount | $ 15,000 | ||||||
Warrants price | $ 0.002 | ||||||
Warrants, fair value | $ 93,748 | ||||||
Excerice of price | 164,285,714 | ||||||
Warrant [Member] | |||||||
Short-Term Debt [Line Items] | |||||||
Warrants price | $ 0.0008 | ||||||
Excerice of price | 164,285,714 | 410,403,571 | |||||
Number of warrants | $ 0 | ||||||
Warrant [Member] | Convertible Notes Payable [Member] | |||||||
Short-Term Debt [Line Items] | |||||||
Debt instrument, face amount | $ 16,500 | $ 38,500 | |||||
Debt instrument unamortized discount | $ 1,650 | $ 7,550 | |||||
Warrants price | $ 0.001 | ||||||
Warrants, fair value | $ 541 | $ 195,178 | |||||
Money Warrants [Member] | |||||||
Short-Term Debt [Line Items] | |||||||
Number of warrants to purchase common stock | 0 |
SCHEDULE OF ACCRUED EXPENSES (D
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Payables and Accruals [Abstract] | ||
Accrued consulting fees | $ 161,550 | $ 161,550 |
Accrued payroll taxes | 227,912 | 215,543 |
Accrued interest | 571,151 | 469,040 |
Accrued others | 2,913 | 5,337 |
Total | $ 963,526 | $ 851,470 |
SCHEDULE OF PREPAID EXPENSES (D
SCHEDULE OF PREPAID EXPENSES (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Prepaid Expenses | ||
Supplier advances for future purchases | $ 339,162 | $ 294,162 |
Reserve for supplier advances | (294,162) | (294,162) |
Net supplier advances | 45,000 | |
Prepaid professional fees | 72,650 | 65,650 |
Deferred stock compensation | 20,500 | |
Total | $ 117,650 | $ 86,150 |
PREPAID EXPENSES (Details Narra
PREPAID EXPENSES (Details Narrative) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Prepaid Expenses | ||
Future reserve for purchases | $ 0 | $ 48,000 |
Total valuation allowance for prepaid | $ 294,162 | $ 294,162 |
CONVERTIBLE NOTES RECEIVABLE (D
CONVERTIBLE NOTES RECEIVABLE (Details Narrative) - USD ($) | 3 Months Ended | 8 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Sep. 30, 2022 | Sep. 30, 2021 | Nov. 01, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Aug. 31, 2022 | Nov. 30, 2021 | |
Short-Term Debt [Line Items] | ||||||||
Debt original issuance discount | $ 16,693 | |||||||
Convertible notes receivable repayments | $ 50,250 | $ 50,250 | ||||||
Amortization of notes receivables | 404,549 | 232,117 | ||||||
Convertible notes receivable | 270,896 | 270,896 | $ 273,480 | |||||
Other Income [Member] | ||||||||
Short-Term Debt [Line Items] | ||||||||
Amortization of notes receivables | 4,210 | $ 4,750 | 16,215 | 6,465 | ||||
Amount of debt expired | 268,750 | |||||||
Convertible Notes Payable [Member] | ||||||||
Short-Term Debt [Line Items] | ||||||||
Convertible notes | 4,609,567 | 4,609,567 | 3,751,760 | |||||
Debt original issuance discount | 183,570 | 183,570 | 283,429 | |||||
Amortization of notes receivables | 123,813 | $ 91,455 | 388,994 | $ 213,924 | ||||
Convertible Notes Payable [Member] | Unrelated Third Party [Member] | ||||||||
Short-Term Debt [Line Items] | ||||||||
Convertible notes | $ 286,550 | |||||||
Debt original issuance discount | $ 26,050 | |||||||
Debt instrument, convertible, conversion Price | $ 0.01 | |||||||
Debt term | 1 year | |||||||
Amortization of notes receivables | 0 | $ 13,070 | ||||||
Convertible Notes Payable [Member] | Third Party [Member] | ||||||||
Short-Term Debt [Line Items] | ||||||||
Convertible notes | 34,596 | 34,596 | ||||||
Debt original issuance discount | $ 3,145 | $ 3,145 | ||||||
Debt instrument, convertible, conversion Price | $ 0.01 | $ 0.01 |
SCHEDULE OF LEASE COST AND BALA
SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION (Details) - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Operating lease cost | $ 60,297 | $ 80,396 |
Short-term lease cost | ||
Total lease cost | 60,297 | 80,396 |
Operating ROU Assets | 43,397 | 93,811 |
Operating lease obligations, current portion | 20,003 | 77,673 |
Operating lease obligations, non-current portion | ||
Total | $ 20,003 | $ 77,673 |
Weighted average remaining lease term (in years) - operating leases | 3 months | 1 year |
Weighted average discount rate-operating leases | 8% | 8% |
Cash paid for amounts included in the measurement of operating lease liabilities | $ 67,553 | $ 95,846 |
SCHEDULE OF OPERATING LEASE LIA
SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Commitments and Contingencies Disclosure [Abstract] | ||
2022 (Remaining three months) | $ 20,270 | |
Total future lease payments | 20,270 | |
Less imputed interest | 267 | |
Total | $ 20,003 | $ 77,673 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | 1 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
Oct. 12, 2018 | Aug. 01, 2017 | Jul. 31, 2015 | Aug. 31, 2022 | Feb. 28, 2021 | Oct. 31, 2015 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2016 | |
Defined Benefit Plan Disclosure [Line Items] | ||||||||||
Common stock shares issued | 7,596,852,214 | 7,330,985,964 | 1,000,000 | |||||||
Note issued | $ 287,252 | $ 535,787 | ||||||||
Shares issued, price per share | $ 0.18 | |||||||||
Accrued liabilities for commissions, expense and taxes | $ 142,500 | |||||||||
Debt instrument periodic payment | $ 3,000 | |||||||||
Equity compensation charges | $ 31,750 | |||||||||
Accrued expenses | $ 19,150 | $ 19,150 | ||||||||
Share based compensation, shares not yet issued | 1,500,000 | |||||||||
Loss contingency, allegations | The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. | |||||||||
Consulting Services Agreement [Member] | Restricted Stock [Member] | ||||||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||||||
Consulting service term | 5 years | |||||||||
Common stock shares issued | 500,000 | |||||||||
Debt instrument, interest rate | 8% | |||||||||
Note issued | $ 50,000 | |||||||||
Consultant Agreement [Member] | ||||||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||||||
Share-based compensation arrangement by share-based payment | 2,500,000 | |||||||||
Consultant Agreement [Member] | Common Stock [Member] | ||||||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||||||
Debt instrument periodic payment | $ 3,000 | |||||||||
Recepto Pharm Leases [Member] | ||||||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||||||
Lease, description | ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. | In February of 2021, we signed an updated lease with extended terms through January 1, 2023. The lease calls for monthly payments of approximately $6,500 with a 4% increase each year. | ||||||||
Lease monthly payments | $ 6,900 | $ 6,500 | ||||||||
Get Credit Healthy, Inc. and Rik Deitsch [Member] | ||||||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||||||
Loss contingency, damages sought, value | $ 100,000 | |||||||||
CSA 8411, LLC [Member] | ||||||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||||||
Long-term debt | $ 91,156 | |||||||||
Accrued interest | $ 60,037 |
SCHEDULE OF RELATED PARTY BALAN
SCHEDULE OF RELATED PARTY BALANCES (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Related Party Transactions [Abstract] | ||
Deferred revenue to a related party | $ 111,011 | |
Accrued interest to a related party | $ 145,508 | $ 147,768 |
SCHEDULE OF RELATED PARTY TRANS
SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Related Party Transactions [Abstract] | ||||
Net sales to a related party | $ 84,580 | $ 154,966 | ||
Bad debt expense (recovery) - related party | (21,799) | (35,000) | 38,000 | |
Rental income from a related party | 10,000 | 10,000 | ||
Interest expense to a related party | $ 4,272 | $ 4,504 | $ 12,740 | $ 13,881 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended |
May 31, 2022 | Sep. 30, 2022 | Sep. 30, 2022 | |
Related Party Transactions [Abstract] | |||
Payment for rent | $ 5,000 | $ 10,000 | $ 10,000 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) | Oct. 31, 2022 | Oct. 27, 2022 | Aug. 31, 2022 | Feb. 28, 2022 | Jan. 31, 2022 |
Subsequent Event [Line Items] | |||||
Debt instrument unamortized discount | $ 16,693 | ||||
Promissory Note [Member] | |||||
Subsequent Event [Line Items] | |||||
Debt instrument unamortized discount | $ 16,693 | $ 16,693 | |||
Non-related Party [Member] | Promissory Note [Member] | |||||
Subsequent Event [Line Items] | |||||
Due from related party | $ 199,000 | ||||
Debt instrument, interest rate, stated percentage | 63.76% | ||||
Subsequent Event [Member] | Non-related Party [Member] | Promissory Note [Member] | |||||
Subsequent Event [Line Items] | |||||
Due from related party | $ 199,000 | ||||
Debt instrument, interest rate, stated percentage | 60.73% | ||||
Subsequent Event [Member] | Convertible Promissory Notes [Member] | Unrelated Third Parties [Member] | |||||
Subsequent Event [Line Items] | |||||
Debt instrument, face amount | $ 57,500 | ||||
Debt instrument unamortized discount | $ 7,500 | ||||
Debt Instrument, Convertible, Conversion Price | $ 0.0006 |